154 related articles for article (PubMed ID: 37688395)
1. Heterocyclic and non-heterocyclic arena of monocarboxylate transporter inhibitors to battle tumorigenesis.
Manisha DS; Ratheesh AK; Benny S; Presanna AT
Chem Biol Drug Des; 2023 Dec; 102(6):1604-1617. PubMed ID: 37688395
[TBL] [Abstract][Full Text] [Related]
2. Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?
Singh M; Afonso J; Sharma D; Gupta R; Kumar V; Rani R; Baltazar F; Kumar V
Semin Cancer Biol; 2023 May; 90():1-14. PubMed ID: 36706846
[TBL] [Abstract][Full Text] [Related]
3. Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents.
Wu P; Zhou Y; Guo Y; Zhang SL; Tam KY
Drug Discov Today; 2021 Mar; 26(3):836-844. PubMed ID: 33450176
[TBL] [Abstract][Full Text] [Related]
4. Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment.
Liu T; Han S; Yao Y; Zhang G
Cancer Manag Res; 2023; 15():957-975. PubMed ID: 37693221
[TBL] [Abstract][Full Text] [Related]
5. Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease.
Felmlee MA; Jones RS; Rodriguez-Cruz V; Follman KE; Morris ME
Pharmacol Rev; 2020 Apr; 72(2):466-485. PubMed ID: 32144120
[TBL] [Abstract][Full Text] [Related]
6. Autoregulation of H
Blaszczak W; Williams H; Swietach P
Br J Cancer; 2022 Oct; 127(7):1365-1377. PubMed ID: 35840734
[TBL] [Abstract][Full Text] [Related]
7. Monocarboxylate transporters in cancer.
Payen VL; Mina E; Van Hée VF; Porporato PE; Sonveaux P
Mol Metab; 2020 Mar; 33():48-66. PubMed ID: 31395464
[TBL] [Abstract][Full Text] [Related]
8. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study.
Mathupala SP; Parajuli P; Sloan AE
Neurosurgery; 2004 Dec; 55(6):1410-9; discussion 1419. PubMed ID: 15574223
[TBL] [Abstract][Full Text] [Related]
9. The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer.
Roseweir AK; Clark J; McSorley ST; vanWyk HC; Quinn JA; Horgan PG; McMillan DC; Park JH; Edwards J
Int J Cancer; 2019 May; 144(9):2320-2329. PubMed ID: 30521130
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1.
Påhlman C; Qi Z; Murray CM; Ferguson D; Bundick RV; Donald DK; Ekberg H
Transpl Int; 2013 Jan; 26(1):22-9. PubMed ID: 23137339
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities.
Kalyanaraman B; Cheng G; Hardy M
Front Oncol; 2022; 12():816504. PubMed ID: 35756631
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic and clinical implications of lactate induced immunosuppression in the tumour microenvironment.
Hayes C; Donohoe CL; Davern M; Donlon NE
Cancer Lett; 2021 Mar; 500():75-86. PubMed ID: 33347908
[TBL] [Abstract][Full Text] [Related]
13. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells.
Amorim R; Pinheiro C; Miranda-Gonçalves V; Pereira H; Moyer MP; Preto A; Baltazar F
Cancer Lett; 2015 Aug; 365(1):68-78. PubMed ID: 26021766
[TBL] [Abstract][Full Text] [Related]
14. A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).
Papakonstantinou E; Vlachakis D; Thireou T; Vlachoyiannopoulos PG; Eliopoulos E
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805725
[TBL] [Abstract][Full Text] [Related]
15. The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters.
Li X; Yu X; Dai D; Song X; Xu W
Oncotarget; 2016 Apr; 7(17):23141-55. PubMed ID: 27009812
[TBL] [Abstract][Full Text] [Related]
16. Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells.
Cheng C; Edin NF; Lauritzen KH; Aspmodal I; Christoffersen S; Jian L; Rasmussen LJ; Pettersen EO; Xiaoqun G; Bergersen LH
Cell Oncol (Dordr); 2012 Jun; 35(3):217-27. PubMed ID: 22700320
[TBL] [Abstract][Full Text] [Related]
17. Targeting lactate transport suppresses in vivo breast tumour growth.
Morais-Santos F; Granja S; Miranda-Gonçalves V; Moreira AH; Queirós S; Vilaça JL; Schmitt FC; Longatto-Filho A; Paredes J; Baltazar F; Pinheiro C
Oncotarget; 2015 Aug; 6(22):19177-89. PubMed ID: 26203664
[TBL] [Abstract][Full Text] [Related]
18. Proton-coupled monocarboxylate transporters in cancer: From metabolic crosstalk, immunosuppression and anti-apoptosis to clinical applications.
Duan Q; Zhang S; Wang Y; Lu D; Sun Y; Wu Y
Front Cell Dev Biol; 2022; 10():1069555. PubMed ID: 36506099
[TBL] [Abstract][Full Text] [Related]
19. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.
Pertega-Gomes N; Felisbino S; Massie CE; Vizcaino JR; Coelho R; Sandi C; Simoes-Sousa S; Jurmeister S; Ramos-Montoya A; Asim M; Tran M; Oliveira E; Lobo da Cunha A; Maximo V; Baltazar F; Neal DE; Fryer LG
J Pathol; 2015 Aug; 236(4):517-30. PubMed ID: 25875424
[TBL] [Abstract][Full Text] [Related]
20. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
